A Phase 3 interventional study of Formoterol/Budesonide and Foraseq in Asthma, sponsored by Eurofarma Laboratorios S.A.. Completed at 5 sites in Brazil. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.
Among the 86 studies testing formoterol in Asthma, this one is the 24th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2011, is one of 48 in phase 3, and was the 52nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 552 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 85 interventional studies. Of the 76 that completed or were terminated, 29 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 86 have an industry lead sponsor. The 10 most frequent:
Eurofarma Laboratorios S.A. is the lead sponsor of 64 studies on the registry; 7 are open to participants now.
Eurofarma Laboratorios S.A. has 7 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 86 studies testing formoterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the three study formulations regarding the clinical control of the symptoms and the patients' compliance to the treatment.
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the three study formulations regarding the clinical control of the symptoms and the patients' compliance to the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
Drug: Formoterol/Budesonide
Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Drug: Foraseq
Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Drug: Alenia
Drug pages: Formoterol · Budesonide
formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Also known as: Formoterol/Budesonide
Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Also known as: Formoterol/Budesonide
Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV)
The primary efficacy analysis was performed by evaluating non-inferiority of Eurofarma's device compared to Alenia® in relation to FEV1 (in liters) in FV in the PP population
Time frame: 12 weeks
FEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups
The mean FEV1 (L) in VF were compared between the three groups using the nonparametric Kruskal-Walllis test and the ITT population. A nonparametric test was used since the variable did not show normal distribution in the Foraseq® group.
Time frame: 12 weeks
| Milestone | Formoterol/Budesonide | Foraseq | Alenia |
|---|---|---|---|
| Started | 184 | 184 | 184 |
| Completed | 154 | 145 | 151 |
| Not completed | 30 | 39 | 33 |
The primary efficacy analysis was performed by evaluating non-inferiority of Eurofarma's device compared to Alenia® in relation to FEV1 (in liters) in FV in the PP population
| Liter | Formoterol/Budesonide | Alenia |
|---|---|---|
| Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV) | 2.53 ± 0.79 | 2.51 ± 0.77 |
The mean FEV1 (L) in VF were compared between the three groups using the nonparametric Kruskal-Walllis test and the ITT population. A nonparametric test was used since the variable did not show normal distribution in the Foraseq® group.
| Liter | Alenia | Formoterol/Budesonide | Foraseq |
|---|---|---|---|
| FEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups | 2.49 ± 0.77 | 2.52 ± 0.80 | 2.46 ± 0.88 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Formoterol/Budesonide | — | 1/154 (0.6%) | 1/154 (0.6%) |
| Foraseq | — | 0/145 (0%) | 0/145 (0%) |
| Alenia | — | 0/151 (0%) | 0/151 (0%) |
| Event | Formoterol/Budesonide | Foraseq | Alenia |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/154 | 0/145 | 0/151 |
| LeukopeniaImmune system disorders | 1/154 | 0/145 | 0/151 |
| Event | Formoterol/Budesonide | Foraseq | Alenia |
|---|---|---|---|
| Left and posterior knee trauma infectionInjury, poisoning and procedural complications | 1/154 | 0/145 | 0/151 |
| Age, Categorical(Participants) | Formoterol/Budesonide | Foraseq | Alenia | Total |
|---|---|---|---|---|
| <=18 years | 28 | 25 | 21 | 74 |
| Between 18 and 65 years | 119 | 112 | 121 | 352 |
| >=65 years | 7 | 8 | 9 | 24 |
| Age, Continuous(years) | Formoterol/Budesonide | Foraseq | Alenia | Total |
|---|---|---|---|---|
| Mean | 38 ± 17 | 39 ± 17 | 39 ± 16 | 39 ± 17 |
| Sex: Female, Male(Participants) | Formoterol/Budesonide | Foraseq | Alenia | Total |
|---|---|---|---|---|
| Female | 99 | 99 | 110 | 308 |
| Male | 55 | 46 | 41 | 142 |
| Region of Enrollment(participants) | Formoterol/Budesonide | Foraseq | Alenia | Total |
|---|---|---|---|---|
| Brazil | 154 | 145 | 151 | 450 |
The record gives a start of Apr 2011, a primary completion of Aug 2011 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2025, 13 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Formoterol · Budesonide